Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.35 USD
0.00 (0.00%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Reneo Pharmaceuticals, Inc. [RPHM]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transformative Merger with OnKure to Close in 2024; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Mavodelpar Pivotal Trial Fails; Development Suspended; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Defining PMM Phase 2b Data Next Month; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
We Continue to Expect Positive Pivotal PMM Data in December; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Competitor PPARa Data Provides Validation For Lead Asset; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Unleashing The Powerhouse of the Cell; Initiating at Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Restoring Energy with REN001 in Pivotal Trial For PMM; Assuming Coverage With Buy Rating and $31 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Reneo Pharmaceuticals, Inc.
Industry: Medical - Drugs
Exploring New Clinical Territory With a Selective PPAR Agonist; Initiating Coverage With a Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
|